Daré Bioscience, Inc. DARE
0.65 USD -0.05 (-6.60%)
Nov 12, 2026, 3:31 PM EST
0.64 Day range 0.6868
0.61 52-week range 3.78
- YTD
- -66.41%
- 1 year
- -67.26%
News
globenewswire.com Daré Bioscience to Host Third Quarter 2026 Financial Results and Company Update Conference Call and Webcast on November 16, 2026 SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising…
globenewswire.com Daré Bioscience Releases Next Episode in “CEO Corner” Video Series Sabrina Martucci Johnson, Founder, President and CEO, discusses numerous potential value drivers expected to power the Company's next phase of growth and commercial success
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares increased by 232.0% to $2.0 during Monday's pre-market session. The company's market cap stands at $62.2 million. AngioDynamics (NASDAQ:ANGO) shares…
benzinga.com Daré Bioscience Receive Additional $1.5M Funding Installment Under Grant Agreement For DARE-LARC1 With this installment, Daré Bioscience has received a total of approximately $43.3 million in non-dilutive funding under the grant agreement. The remaining approximately $5.6 million of the up to…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Biomea Fusion (NASDAQ:BMEA) stock increased by 11.0% to $1.51 during Monday's after-market session. The market value of their outstanding shares is at $102.9 million. iTonic Holdings…
benzinga.com Daré Bioscience To Present Clinical Data From A Phase 1 Study Evaluating Sildenafil Cream, 3.6% Investigational Product At The Sexual Medicine Society Of North America Meeting, October 8-11 linical data from a Phase 1 study that evaluated the Company’s proprietary Sildenafil Cream, 3.6% investigational product (Sildenafil Cream) will be presented at the Annual Fall Scientific Meeting of…
benzinga.com Daré Bioscience Receives U.S. Patent For Its Pharmaceutical Compositions Formulated For Topical Application Comprising Lopinavir, Ritonavir To Treat Cervical Pathologies Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced…- benzinga.com Daré Bioscience Announces Publication Of Results From A Phase 1 Clinical Study Evaluating Safety And Systemic Pharmacokinetics Of Topical Sildenafil Cream, 3.6%, In Healthy Adult Men In The Journal Sexual Medicine; At 71 Mg Topical Dose, Mean Maximum Plasma Concentration Of Sildenafil Was ~187-Fold Lower Than Following A 50 Mg Oral Dose The article, titled, "An open-label, single-dose, randomized, parallel-group study of the safety and relative bioavailability of topical sildenafil cream vs oral sildenafil in healthy male adults,"…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers EXoZymes (NASDAQ:EXOZ) stock increased by 7.5% to $7.18 during Wednesday's after-market session. The market value of their outstanding shares is at $58.5 million. AEON Biopharma (AMEX:AEON)…- benzinga.com Daré Bioscience Announces Publication Of Clinical Study Results From Its Proprietary Formulation Of Topical Sildenafil Cream, 3.6%, In Menopause In The Journal Of The Menopause Society; 3.6% Was Well Tolerated Across All Evaluated Doses In The Clinical Study, With Minimal Systemic Exposure The peer-reviewed article, titled, "A phase 1, open-label, within-participant dose-escalation study to evaluate the safety and pharmacokinetics of topical sildenafil cream in healthy postmenopausal…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular session. The company's market cap stands at $23.7 million. The company's, Q2 earnings came out yesterday.
benzinga.com Daré Bioscience Announces $6M Offering Of 4,379,581 Shares (Or Pre-Funded Warrants To Purchase Shares Of Common Stock In Lieu Thereof) At $1.37/Share Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced…- benzinga.com Dare Bioscience Reports Q2 2026 Results: Full Earnings Call Transcript Dare Bioscience (NASDAQ:DARE) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga…
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Akanda (NASDAQ:AKAN) stock rose 109.4% to $10.49 during Thursday's after-market session. The company's market cap stands at $2.9 million. Capricor Therapeutics (NASDAQ:CAPR) stock moved…
benzinga.com Dare Bioscience Q2 EPS $(0.20) Beats $(0.24) Estimate, Sales $187.546K Beat $2.000K Estimate Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.24) by 16.67 percent. This is a 55.56 percent increase over losses of…- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares increased by 322.6% to $2.95 during Monday's regular session. The company's market cap stands at $33.0 million. Advanced Biomed (NASDAQ:ADVB) stock…
benzinga.com Dare Biosciences Receives Second $1M Tranche Of NIH Funding Receipt of award notice for second $1.0 million tranche of NIAID funding brings total NIH funding award for DARE-HPV to $2.0 millionFunding award milestone follows Daré's announcement last week of…
benzinga.com Daré Bioscience Initiates Phase 2 Clinical Study Of DARE-HPV Treatment The Phase 2 study is a randomized, placebo-controlled, double-blind trial designed to evaluate the safety and antiviral activity of a lower and higher DARE-HPV dose compared with placebo in…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Dare Bioscience Q1 2026 Earnings Call: Complete Transcript
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com Dare Bioscience Q1 EPS $(0.20) Beats $(0.27) Estimate, Sales $152.455K Miss $984.667K Estimate Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.27) by 25.93 percent. This is a 60 percent increase over losses of…
benzinga.com Earnings Scheduled For May 14, 2026 
benzinga.com Why Is Nano-Cap Dare Bioscience Stock Trading Higher On Tuesday? Dare Bioscience stock climbed after Phase 3 interim data for Ovaprene showed expected pregnancy rates and no trial changes by DSMB.
benzinga.com Dare Bioscience Announces Interim Safety And Efficacy Results From Phase 3 Clinical Trial Of Ovaprene Second Positive DSMB Review Supports Continued Study ProgressInterim Phase 3 Results Support Ovaprene's Differentiation as a First-in-Category, Hormone-Free, Intravaginal Monthly Contraceptive- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Dare Bioscience Q4 EPS $(0.02) Beats $(0.43) Estimate, Sales $1.024M Beat $375.750K Estimate Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.43) by 95.37 percent. This is a 96.92 percent increase over losses of…
- benzinga.com Earnings Scheduled For March 26, 2026
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Daré Bioscience Gets ~$2M Funding From National Institutes Of Health's Division For Its Intravaginal Ring DARE-PTB1 For Prevention Of Preterm Birth Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Daré Bioscience Announces FDA Clears Its Investigational New Drug Application For DARE-HPV To Initiate Planned Phase 2 Clinical Study For Papillomavirus Infection Treatment Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced…
- benzinga.com Earnings Scheduled For November 13, 2025
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Earnings Scheduled For August 14, 2025
benzinga.com Crude Oil Moves Lower; Daré Bioscience Shares Jump - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com US Stocks Edge Lower; Fastenal Posts Upbeat Earnings - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com Earnings Scheduled For May 13, 2025
- benzinga.com Earnings Scheduled For March 31, 2025
- benzinga.com Earnings Scheduled For November 14, 2024
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com Why James Hardie Industries Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Why H&E Equipment Services Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session